Want to see POM full AI Analyst Report?
POM Stock Chart & Stats
$0.31
--
Market closed
$0.31
--
Day’s Range― - ―
52-Week Range$1.15 - $115.74
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.20M
Market Cap
$11.93M
Enterprise Value$505.22M
Total Cash (Recent Filing)$2.11B
Total Debt (Recent Filing)$37.66B
Price to Earnings (P/E)―
Beta0.16
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,774,573
10 Day Avg. Volume781,994
30 Day Avg. Volume2,198,746
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-4.75
Price to Sales (P/S)5.39
P/FCF Ratio-14.43
Enterprise Value/Market Cap42.35
Enterprise Value/Revenue0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda0.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthPomDoctor delivered sustained top-line expansion (2025 revenue up ~17%), with strong adoption in online channels. Continued demand for chronic disease care and digital delivery suggests a growing addressable market and scalable revenue base that can support long-term strategic investments.
Integrated Business ModelThe firm operates an internet-hospital plus pharmaceutical supply-chain platform linking patients, physicians, pharmacies and suppliers. This one-stop chronic-disease focus can create cross-sell synergies, recurring service flows and patient/provider stickiness that bolster durable competitive positioning.
Material R&D InvestmentManagement sharply increased R&D (328.5% in 2025) toward AI, medical-grade wearables and full-cycle chronic care. Such sustained capability-building can create differentiated products and platform advantages over time if R&D converts to validated solutions and tighter clinical or payer integration.
Bears Say
Worsening ProfitabilityAlthough revenue grew, gross margin compressed and net loss widened in 2025, indicating the company has not achieved profitable scale. Persistent negative margins point to structural unit-economics issues—weak pricing power or high operating intensity—that threaten long-term earnings durability.
Sharp Cash BurnFree cash flow deteriorated materially to about -$149M in 2025 from roughly -$16M prior, with operating cash flow negative each year. The pronounced cash burn increases reliance on external financing, heightens dilution risk and constrains the company's ability to invest or weather shocks over the medium term.
Weak Balance Sheet & Governance RiskThe balance sheet shows persistent negative equity and rising debt (to ~$455M by 2025), materially weakening financial flexibility. Combined with disclosed internal control weaknesses and a recent auditor change, this elevates solvency and governance risks that can impair access to capital and partner confidence.
PomDoctor Ltd. Unsponsored ADR News
POM FAQ
What was PomDoctor Ltd. Unsponsored ADR’s price range in the past 12 months?
PomDoctor Ltd. Unsponsored ADR lowest stock price was $1.15 and its highest was $115.74 in the past 12 months.
What is PomDoctor Ltd. Unsponsored ADR’s market cap?
PomDoctor Ltd. Unsponsored ADR’s market cap is $11.93M.
When is PomDoctor Ltd. Unsponsored ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PomDoctor Ltd. Unsponsored ADR’s earnings last quarter?
Currently, no data Available
Is PomDoctor Ltd. Unsponsored ADR overvalued?
According to Wall Street analysts PomDoctor Ltd. Unsponsored ADR’s price is currently Overvalued.
Does PomDoctor Ltd. Unsponsored ADR pay dividends?
PomDoctor Ltd. Unsponsored ADR does not currently pay dividends.
What is PomDoctor Ltd. Unsponsored ADR’s EPS estimate?
PomDoctor Ltd. Unsponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PomDoctor Ltd. Unsponsored ADR have?
PomDoctor Ltd. Unsponsored ADR has 6,774,573 shares outstanding.
What happened to PomDoctor Ltd. Unsponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PomDoctor Ltd. Unsponsored ADR?
Currently, no hedge funds are holding shares in POM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PomDoctor Ltd. Unsponsored ADR
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.17% Other Institutional Investors
99.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---